COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran

Atefeh Vaezi; Alipasha Meysamie

doi:10.3390/vaccines10010037

COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran

Vaccines (Basel). 2021 Dec 29;10(1):37. doi: 10.3390/vaccines10010037.

Authors

Atefeh Vaezi¹, Alipasha Meysamie^{2

3}

Affiliations

¹ Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.
² Department of Community Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran 1416753955, Iran.
³ Community Based Participatory Research Center, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran 1416753955, Iran.

Abstract

COVID-19 vaccines are supposed to be critical measure for ending the pandemic. Governments had to decide on the type of vaccine to provide for their population. In this decision-making process, cost-effectiveness analysis is considered a helpful tool. This study is a cost-effectiveness analysis utilized to calculate the incremental cost per averted disability-adjusted life year (DALY) by vaccination compared to no vaccination for different COVID-19 vaccines. The incremental cost-effectiveness ratio (ICER) for a vaccination with COVID-19 vaccines was estimated at 6.2 to 121.2 USD to avert one DALY and 566.8 to 10,957.7 USD per one death. The lowest and highest ICERs belong to Ad26.COV2.S and CoronaVac, respectively. Considering the scenario of Iran, vaccines that are recommended include ad26.cov2.s, chadox1-S, rAd26-S + rAd5-S, and BNT162b2 in the order of recommendation.

Keywords: SARS-CoV-2; SARS-CoV-2 vaccines; cost-effectiveness analysis; effectiveness.